CRDF Q2 2021 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68,000+58.1% YoY

Gross Profit

$68,000100.0% margin

Operating Income

-$7M-10130.9% margin

Net Income

-$7M-9936.8% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-5.6%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$144M

Total Liabilities

$5M

Stockholders' Equity

$139M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68,000	$43,000	+58.1%
Gross Profit	$68,000	$43,000	+58.1%
Operating Income	-$7M	-$4M	-67.9%
Net Income	-$7M	-$4M	-63.8%